2seventy Bio Anticipate KarMMa-9 Study Study Decision To Conserve Over $80M In Near-Term Expenditures And Accelerate Path To Breakeven In 2025
2seventy Bio Anticipate KarMMa-9 Study Study Decision To Conserve Over $80M In Near-Term Expenditures And Accelerate Path To Breakeven In 2025
2seventy Bio預計KarMMa-9研究決定在近期支出上節省超過$8000萬，並加速2025年實現盈虧平衡的路徑
2seventy Bio Anticipate KarMMa-9 Study Study Decision To Conserve Over $80M In Near-Term Expenditures And Accelerate Path To Breakeven In 2025
2seventy Bio預計KarMMa-9研究決定在近期支出上節省超過$8000萬，並加速2025年實現盈虧平衡的路徑
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間